Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma

Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma

The NovoTTF-100A device emits frequency-tuned alternating electric fields that interfere with tumor cell mitosis. In phase III trial for recurrent glioblastomas, NovoTTF-100A was shown to have equivalent efficacy and less toxicity when compared to Best Physician's Choice (BPC) chemotherapy. We...

Full description

Bibliographic Details
Main Authors: Wong, Eric T, Lok, Edwin, Swanson, Kenneth D, Gautam, Shiva, Engelhard, Herbert H, Lieberman, Frank, Taillibert, Sophie, Ram, Zvi, Villano, John L
Format: Online
Language:English
Published: BlackWell Publishing Ltd 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101750/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101750/

Similar Items